E11
Conditions
Interventions
Group 1: This study investigates the efficacy of the GlucoTab system for glycemic management using glucose
measurements derived from a continuous glucose
monitoring system in non-critically ill pati
Sponsors
Medizinische Universität Graz
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: -Informed consent obtained after being advised of the nature of the study -Male or female aged =18 years -Type 2 diabetes (treated with diet, oral agents, non-insulin injected anti-diabetic medicine, insulin therapy or any combination of the four) or newly diagnosed hyperglycemia which requires s.c. insulin therapy
Exclusion criteria
Exclusion criteria: - Type 1 diabetes, gestational diabetes - Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the patient - Hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require intravenous insulin therapy - Pregnancy - Any mental condition rendering the patient incapable of giving his consent - Known or suspected allergy to adhesive material/tape - Skin pathologies that hinder application of a CGM sensor - Continuous parenteral nutrition - Participation in another trial which can influence outcome of the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean percentage of blood glucose measurements in the target range 70 to 140 mg/dl, as calculated by all premeal and bedtime blood glucose values measured = 24 hours after start of therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety - Hypoglycemia (140-140-100 mg/dl (cf. ISO 15197: 2013) | — |
Countries
Austria
Contacts
Public ContactJulia Mader
Medizinische Universität Graz
Outcome results
None listed